US Patent 8,530,668 Crystal X-Ray Diffraction Peaks: Scope, Claim Construction Targets, and U.S. Patent Landscape
The U.S. Drug Patent 8,530,668 is directed to a specific polymorph (or solid-state form) of an active ingredient defined by stereochemistry and a defined X-ray powder diffraction (XRPD) peak set, plus downstream formulation claims that cover pharmaceutical compositions using that crystal as the active ingredient for thrombopoietin receptor agonist and platelet production regulation functions.
What does US 8,530,668 actually claim in plain scope terms?
Claim 1 is the core: it locks the invention to a crystal of a defined chemical entity (S-(E)-3-(2,6-dichloro-4-{4-[3-(1-hexyloxyethyl)-2-methyloxyphenyl]thiazol-2-ylcarbamoyl}phenyl)-2-methylacrylic acid) that is characterized by an XRPD pattern with peaks at specific two-theta values.
Claim 2 covers pharmaceutical compositions that use that crystal as the active ingredient.
Claims 3 and 4 further specify the intended therapeutic function using standard dosage-form functional language (thrombopoietin receptor agonist; platelet production regulating agent), without adding additional structural limitations beyond the claimed crystal and composition.
What chemical identity is fixed by Claim 1?
Claim 1 fixes:
- The molecule identity and stereochemical descriptors: (S)-(E)-3-(2,6-dichloro-4-{4-[3-(1-hexyloxyethyl)-2-methyloxyphenyl]thiazol-2-ylcarbamoyl}phenyl)-2-methylacrylic acid.
- The solid form: a “crystal” characterized by XRPD.
- The XRPD fingerprint: at least these peaks at 17.8°, 21.1°, 22.5°, 23.3°, 24.1°, 24.4° two-theta.
What the claim construction pressure points are (where scope can expand or narrow)?
In polymorph XRPD claims, claim scope typically hinges on:
- Whether the XRPD peak list is “comprising” or “consisting of”. The claim text reads like an “X-ray powder diffraction pattern comprising peaks located at…” which generally implies the presence of those peaks rather than an exhaustive set.
- Peak tolerance (often instrument-, method-, and reference-dependent). The claim specifies nominal two-theta values; practical infringement analysis turns on whether accused samples show peaks within a tolerance window that courts adopt.
- “Crystalline” determination. The claim recites “crystal characterized by” XRPD peaks. Amorphous or different crystalline forms that miss one or more peaks may avoid.
- Stereochemistry and E-geometry lock. Any salt, racemate, or Z-isomer form could avoid if it does not meet the exact stereochemical identity requirement (though in practice this is usually fixed by the active substance itself).
Which parts of the claims are most enforceable?
Claim 1: polymorph capture via XRPD peak set
Claim 1 is the enforceable anchor because it provides the “product-by-XRPD” characterization. If a competitor sells any crystalline form that:
- is the same (S)-(E) active, and
- exhibits XRPD peaks at the specified positions (within any accepted tolerance),
then the product likely falls within Claim 1 even if it is produced by a different process.
Claims 2-4: formulation and use claims derived from Claim 1
Claims 2-4 generally do not add additional chemistry barriers beyond the requirement that the active is the claimed crystal.
- Claim 2 is broad: “a pharmaceutical composition comprising, as an active ingredient, the crystal.”
- Claim 3 and 4 are use/function claims attached to the same composition; they add no extra structural limitation but can broaden infringement theory when therapeutic purpose and labeling align.
How should you interpret the XRPD peak list as a litigation and clearance tool?
Claim 1’s XRPD requirement is the main design-around axis. If an accused solid:
- shows all or substantially all of the claimed characteristic peaks, it is vulnerable; and
- omits one or more peaks or shifts them outside the practical tolerance window, it is less likely to infringe.
Peak “comprising” language typically expands scope
Because Claim 1 uses “comprising peaks located at” those angles, a sample can have additional peaks and still infringe if the listed peaks are present. This makes “peak engineering” harder than if the claim required an exact pattern.
The “crystal” modifier can be a factual battleground
If an accused product is argued to be amorphous, partially amorphous, or a different polymorph category, infringement can be contested on whether the XRPD pattern meets the “crystal characterized by” requirement.
What is the likely patent coverage boundary: salts, hydrates, and other solid forms?
The claims, as given, are limited to a “crystal” and are identified by XRPD peaks. They do not expressly mention:
- salts
- solvates
- hydrates
- different particle sizes or co-crystals
In practice, coverage can still extend to certain forms if they are crystals of the same active and produce the same XRPD fingerprint at the claimed peaks. But if the accused solid is:
- a different hydrate/solvate that shifts peaks or changes diffraction features, or
- a different polymorph where one or more listed peaks shift beyond tolerance,
then it may avoid.
How broad are the formulation claims (Claim 2) in the U.S. context?
Claim 2 is a composition claim covering “a pharmaceutical composition” with the claimed crystal as the active ingredient. This can include:
- tablets, capsules, or powders reconstituted into dosage forms
- compositions that add typical excipients
as long as they incorporate the claimed XRPD-defined crystal as the active ingredient.
There is no limitation in Claim 2 restricting:
- dosage form,
- excipient type,
- particle size range,
- coating,
- manufacturing method,
- or release profile.
How strong are the method-of-use elements (Claims 3 and 4)?
Claims 3 and 4 use functional therapeutic language:
- “effective as a thrombopoietin receptor agonist”
- “effective as the platelet production regulating agent”
These elements likely track the pharmacological mechanism of the underlying active. In enforcement, the patent holder generally needs to show the accused composition contains the claimed crystal and is used/marketed for the claimed therapeutic purpose consistent with its FDA-approved or otherwise supported labeling.
What U.S. patent landscape issues matter around a polymorph/XRPD patent like 8,530,668?
A practical landscape analysis for a polymorph claim typically looks at three layers:
- Family scope around the same active and solid-state forms
- other polymorphs for the same active
- salts/hydrates/solvates
- process patents for manufacturing the XRPD-defined crystal
- Downstream formulation patents
- specific excipient systems
- particle engineering
- controlled-release forms
- Freedom-to-operate risk against generic solid-state changes
- whether the ANDA filer can choose a different polymorph with a different XRPD pattern
- whether the generic’s API certification triggers label/use carve-outs
Patent estate mapping approach for U.S. decisions tied to 8,530,668
Because your request is anchored to the specific U.S. patent 8,530,668 and the claim text you provided, the relevant “estate” analysis must focus on what can be inferred from the claim type:
Solid-form claim cluster likely present in the same family
Even without seeing the rest of the written description, an XRPD peak-set crystal claim usually sits alongside:
- related claims for other polymorphs (different peak sets)
- other crystal characterization methods (DSC, IR, Raman, SSNMR)
- process-to-crystal claims
Typical competitor strategy against XRPD polymorph patents
- Develop and commercialize an alternative solid form that avoids the exact peak signature.
- Formulate the same API but change the solid-state properties so the XRPD peaks shift outside the list.
- Pursue licensing where the crystallinity can be managed via manufacturing controls that yield the licensed form.
What generic entry risks exist if a filer uses “the same API but different solid form”?
If a generic uses the same molecular active but a different polymorph or solvate that does not reproduce the listed peak set, it may avoid Claim 1. The litigation risk becomes:
- whether the accused solid still shows peaks at those two-theta positions in its XRPD profile under the claim’s measurement conventions; and
- whether the accused product uses a crystalline form that is “substantially equivalent” to the claimed form in terms of the asserted peaks.
What litigation and Orange Book status affect enforcement leverage?
No Orange Book listing, FDA approval date, exclusivity status, or litigation docket details were provided. Without those, an enforceability/timing analysis tied to FDA and generic entry cannot be completed from your input set alone.
Key “claim-scope” checklist for infringement and design-around
Infringement checklist for product liability/ANDA disputes
- Is the API the exact (S)-(E) active compound in Claim 1?
- Does the API in the accused product meet the “crystal characterized by XRPD pattern comprising peaks at 17.8, 21.1, 22.5, 23.3, 24.1, 24.4” (two-theta)?
- Does the accused formulation contain that crystal as the active ingredient?
- Is the product marketed/used as a thrombopoietin receptor agonist / platelet production regulating agent in a manner consistent with Claims 3-4?
Design-around checklist for a competitor
- Swap to a solid form whose XRPD does not include one or more of the listed peaks (or shifts them outside the tolerated range).
- Ensure the commercial API has a distinct XRPD fingerprint under the relevant measurement method.
- If the same active crystal is unavoidable, consider licensing or manufacturing controls that explicitly yield a non-infringing form.
What formulations are protected by 8,530,668?
Protected formulations are those where:
- the active ingredient is the claimed XRPD-defined crystal, and
- the composition is used to achieve the claimed pharmacological effect.
The claim does not restrict excipients or dosage format, so protection likely covers most conventional oral or injectable formulations that use the claimed crystal without changing the solid form.
Key takeaways
- US 8,530,668 is a solid-state polymorph patent built around an XRPD peak fingerprint for a specific (S)-(E) active drug.
- Claim 1 is the scope-defining element; it requires the claimed active to exist as a crystal whose XRPD includes peaks at 17.8°, 21.1°, 22.5°, 23.3°, 24.1°, and 24.4° (two-theta).
- Claims 2-4 are downstream: they cover any pharmaceutical composition using that crystal and compositions used as a thrombopoietin receptor agonist / platelet production regulating agent.
- Competitor clearance risk is mainly driven by whether the accused API’s XRPD profile reproduces the claimed peak list within practical tolerance and measurement conditions.
FAQs
1) Does Claim 1 require the XRPD pattern to match exactly, or just include the listed peaks?
Claim 1 uses “comprising peaks,” which generally means the pattern must include the listed peaks; additional peaks can exist.
2) Can a different polymorph avoid infringement if it still contains the same API?
Yes, if the alternative polymorph’s XRPD lacks one or more of the claimed peak positions (within the relevant measurement/tolerance used in infringement analysis).
3) Are salts or hydrates covered by 8,530,668?
Coverage depends on whether they are “crystals” of the same active that still produce the claimed XRPD peak set. The claim text provided does not expressly list salts/hydrates.
4) Do formulation excipients or dosage form types matter for Claim 2?
Not in the claim text provided. Claim 2 covers any pharmaceutical composition that includes the claimed crystal as the active ingredient.
5) What is the practical value of Claims 3 and 4 in litigation?
They support enforcement tied to the therapeutic purpose of the composition, typically aligning with labeling and use as a thrombopoietin receptor agonist and platelet production regulating agent, without adding structural limitations beyond the claimed crystal.
References
- U.S. Patent No. 8,530,668.
